Gottlieb Renews Call For New Opioid Review Paradigm As Democrats Prepare For House Control

 
• By Michael Cipriano
  
Generate a summary of this article
Listen to this article
Beta

US FDA's controversial approval of Dsuvia may prompt incoming House Democrats to pay special attention to commissioner's remarks on how agency reviews opioids. 

Medical advice and medication guidance and prescription drugs health consultation as a giant pill shaped as a lighthouse beacon with 3D illustration elements.

US FDA Commissioner Scott Gottlieb renewed his pitch for the agency to adopt a new paradigm for reviewing future opioid applications on the heels of the controversial Dsuvia (sufentanil sublingual) approval during a Nov. 8 speech, although this time he likely has a new audience listening: the upcoming Democrat-controlled House of Representatives.

Speaking at a private National Comprehensive Cancer Network (NCCN)/American Society of Clinical Oncology (ASCO) workshop, Gottlieb reiterated his desire to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Elections

US Presidential Elections: Are Prescription Drug Pricing Reforms Losing Political Luster?

 
• By Cathy Kelly

Neither Kamala Harris nor Donald Trump mentioned drug pricing reforms in their presidential convention speeches.

FDA Disruption: If Trump Wins, Could Big Changes Be Coming?

 
• By Ramsey Baghdadi

The agency is clearly on the radar of former President Trump and his new coterie of tech moguls.

UK Election Pledges: ‘Nimble’ Regulation, an MRA With the EU, Faster Access & More Efficient Trials

 
• By Ian Schofield

With the 4 July UK general election less than two weeks away, the Pink Sheet looks at the manifestos published by the major political parties and finds pledges to drive innovation, boost clinical trial activity and speed up regulatory procedures.

Biden vs Trump On Drug Pricing And Unfinished Business

 
• By Cathy Kelly

While more significant reforms are less likely under a second Biden term unless Democrats control both chambers of Congress, former President Trump could look to put his stamp on drug pricing reform by resurrecting one of his former policies involving international reference pricing and Medicare Part B drugs. 

More from Legislation

PBMs and Vertical Integration: CBO Adds To Growing Concerns About Negative Impacts

 
• By Sarah Karlin-Smith

Congressional Budget Office responses to questions from US lawmakers on pharmacy benefit managers could add to the momentum for PBM reforms to go further than the current leading proposals.

Beyond BIOSECURE: Lawmakers Flag US Clinical Trial Partnerships With Chinese Military Hospitals

 
• By Cathy Kelly

Letter to US FDA by a bipartisan group of House members cites clinical trials sponsored by Eli Lilly and Pfizer as examples of a widespread industry practice. But any legislation to curtail such practices is not expected to be part of the BIOSECURE Act.

FDA Disruption: If Trump Wins, Could Big Changes Be Coming?

 
• By Ramsey Baghdadi

The agency is clearly on the radar of former President Trump and his new coterie of tech moguls.